These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 2584703

  • 1. Effects of T cell depletion in radiation bone marrow chimeras. III. Characterization of allogeneic bone marrow cell populations that increase allogeneic chimerism independently of graft-vs-host disease in mixed marrow recipients.
    Sykes M, Chester CH, Sundt TM, Romick ML, Hoyles KA, Sachs DH.
    J Immunol; 1989 Dec 01; 143(11):3503-11. PubMed ID: 2584703
    [Abstract] [Full Text] [Related]

  • 2. Effects of T cell depletion in radiation bone marrow chimeras. I. Evidence for a donor cell population which increases allogeneic chimerism but which lacks the potential to produce GVHD.
    Sykes M, Sheard M, Sachs DH.
    J Immunol; 1988 Oct 01; 141(7):2282-8. PubMed ID: 3049804
    [Abstract] [Full Text] [Related]

  • 3. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
    Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Stephany D, Sachs DH.
    J Immunol; 1986 Jan 01; 136(1):28-33. PubMed ID: 2933464
    [Abstract] [Full Text] [Related]

  • 4. Graft-versus-leukemia effect using mixed allogeneic bone marrow transplantation.
    Sykes M, Bukhari Z, Sachs DH.
    Bone Marrow Transplant; 1989 Sep 01; 4(5):465-74. PubMed ID: 2790325
    [Abstract] [Full Text] [Related]

  • 5. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
    Azuma E, Yamamoto H, Kaplan J.
    J Immunol; 1989 Sep 01; 143(5):1524-9. PubMed ID: 2668409
    [Abstract] [Full Text] [Related]

  • 6. Achieving alloengraftment without graft-versus-host disease: approaches using mixed allogeneic bone marrow transplantation.
    Sykes M, Sharabi Y, Sachs DH.
    Bone Marrow Transplant; 1988 Sep 01; 3(5):379-86. PubMed ID: 3056545
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T cell-depleted marrow for the promotion of engraftment.
    Blazar BR, Hirsch R, Gress RE, Carroll SF, Vallera DA.
    J Immunol; 1991 Sep 01; 147(5):1492-503. PubMed ID: 1831826
    [Abstract] [Full Text] [Related]

  • 9. Mixed allogeneic chimerism in the rat. Donor-specific transplantation tolerance without chronic rejection for primarily vascularized cardiac allografts.
    Colson YL, Zadach K, Nalesnik M, Ildstad ST.
    Transplantation; 1995 Nov 15; 60(9):971-80. PubMed ID: 7491703
    [Abstract] [Full Text] [Related]

  • 10. Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras. I. Development of a null cell population suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component.
    Sykes M, Eisenthal A, Sachs DH.
    J Immunol; 1988 May 01; 140(9):2903-11. PubMed ID: 2966200
    [Abstract] [Full Text] [Related]

  • 11. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR, Pearson DA, Swenson K, Zhao G, Sachs J, Yang YG, Sykes M.
    Biol Blood Marrow Transplant; 1999 May 01; 5(3):133-43. PubMed ID: 10392959
    [Abstract] [Full Text] [Related]

  • 12. Alloengraftment in IL-2-treated mice.
    Sykes M, Pearson DA.
    Bone Marrow Transplant; 1992 Aug 01; 10(2):157-63. PubMed ID: 1525605
    [Abstract] [Full Text] [Related]

  • 13. Donor T cell and host NK depletion improve the therapeutic efficacy of allogeneic bone marrow cell reconstitution in the nonmyeloablatively conditioned tumor-bearing host.
    Hummel S, Wilms D, Vitacolonna M, Zöller M.
    J Leukoc Biol; 2002 Nov 01; 72(5):898-912. PubMed ID: 12429711
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. IL-7 drives donor T cell proliferation and can costimulate cytokine secretion after MHC-matched allogeneic bone marrow transplantation.
    Levy RB, Jones M, Hamilton BL, Paupe J, Horowitz T, Riley R.
    J Immunol; 1995 Jan 01; 154(1):106-15. PubMed ID: 7995931
    [Abstract] [Full Text] [Related]

  • 19. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR, Majewski D, Hanson G.
    Biol Blood Marrow Transplant; 1999 Jan 01; 5(4):222-30. PubMed ID: 10465102
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.